Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 79.32 Million SEK | 983.13% |
| 2022 | 7.32 Million SEK | 158.64% |
| 2021 | 2.83 Million SEK | -57.5% |
| 2020 | 6.66 Million SEK | 42.32% |
| 2019 | 4.68 Million SEK | -9.49% |
| 2018 | 5.17 Million SEK | 145.45% |
| 2017 | 2.1 Million SEK | 1463.26% |
| 2016 | 134.77 Thousand SEK | -25.24% |
| 2015 | 180.28 Thousand SEK | -20.15% |
| 2014 | 225.78 Thousand SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 244.54 Thousand SEK | -42.4% |
| 2010 | 424.54 Thousand SEK | -11.55% |
| 2009 | 480 Thousand SEK | -86.9% |
| 2008 | 3.66 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 77.51 Million SEK | -1.32% |
| 2024 Q1 | 78.54 Million SEK | -0.98% |
| 2023 Q2 | 5.71 Million SEK | -10.81% |
| 2023 Q1 | 6.4 Million SEK | -12.58% |
| 2023 Q3 | 80.58 Million SEK | 1311.28% |
| 2023 FY | 79.32 Million SEK | 983.13% |
| 2023 Q4 | 79.32 Million SEK | -1.57% |
| 2022 Q3 | 10.18 Million SEK | 69.27% |
| 2022 FY | 7.32 Million SEK | 158.64% |
| 2022 Q1 | 6.48 Million SEK | 128.86% |
| 2022 Q2 | 6.01 Million SEK | -7.19% |
| 2022 Q4 | 7.32 Million SEK | -28.06% |
| 2021 Q3 | 3.88 Million SEK | -14.02% |
| 2021 Q4 | 2.83 Million SEK | -27.19% |
| 2021 Q2 | 4.52 Million SEK | 111.85% |
| 2021 FY | 2.83 Million SEK | -57.5% |
| 2021 Q1 | 2.13 Million SEK | -67.95% |
| 2020 Q2 | 3.39 Million SEK | 71.34% |
| 2020 FY | 6.66 Million SEK | 42.32% |
| 2020 Q3 | 2.84 Million SEK | -16.25% |
| 2020 Q4 | 6.66 Million SEK | 134.23% |
| 2020 Q1 | 1.98 Million SEK | -57.66% |
| 2019 Q3 | 4.68 Million SEK | 59.22% |
| 2019 Q4 | 4.68 Million SEK | -0.01% |
| 2019 Q2 | 2.94 Million SEK | 0.0% |
| 2019 FY | 4.68 Million SEK | -9.49% |
| 2019 Q1 | 2.94 Million SEK | -43.15% |
| 2018 Q4 | 5.17 Million SEK | -30.65% |
| 2018 Q2 | 9.69 Million SEK | 31.41% |
| 2018 Q1 | 7.37 Million SEK | 250.13% |
| 2018 FY | 5.17 Million SEK | 145.45% |
| 2018 Q3 | 7.45 Million SEK | -23.08% |
| 2017 FY | 2.1 Million SEK | 1463.26% |
| 2017 Q4 | 2.1 Million SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q4 | 134.77 Thousand SEK | -0.17% |
| 2016 FY | 134.77 Thousand SEK | -25.24% |
| 2016 Q2 | 135 Thousand SEK | 0.0% |
| 2016 Q3 | 135 Thousand SEK | 0.0% |
| 2016 Q1 | 135 Thousand SEK | -25.12% |
| 2015 Q3 | 180 Thousand SEK | 0.0% |
| 2015 Q1 | 180 Thousand SEK | -20.28% |
| 2015 Q2 | 180 Thousand SEK | 0.0% |
| 2015 FY | 180.28 Thousand SEK | -20.15% |
| 2015 Q4 | 180.28 Thousand SEK | 0.16% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | 225.78 Thousand SEK | 0.0% |
| 2014 FY | 225.78 Thousand SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2012 FY | - SEK | -100.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q1 | - SEK | -100.0% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q4 | 244.54 Thousand SEK | 0.0% |
| 2011 FY | 244.54 Thousand SEK | -42.4% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q4 | 424.54 Thousand SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q1 | - SEK | -100.0% |
| 2010 FY | 424.54 Thousand SEK | -11.55% |
| 2009 Q4 | 480 Thousand SEK | 0.0% |
| 2009 Q1 | - SEK | 0.0% |
| 2009 FY | 480 Thousand SEK | -86.9% |
| 2008 FY | 3.66 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -392.763% |
| Ziccum AB (publ) | 857 Thousand SEK | -9155.543% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -1493.091% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -223.914% |
| Intervacc AB (publ) | 181 Thousand SEK | -43723.204% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -284.843% |
| Active Biotech AB (publ) | 3 Million SEK | -2544.0% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | -31.538% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -1486.4% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | -11.078% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -913.286% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -18607.547% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 26.961% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -2483.713% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -2974.419% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -7832.0% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 91.899% |
| Camurus AB (publ) | 24.5 Million SEK | -223.663% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -187.746% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 90.849% |
| Cyxone AB (publ) | 858 Thousand SEK | -9144.755% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -4535.885% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -115.497% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -11809.91% |
| SynAct Pharma AB | 637 Thousand SEK | -12352.119% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -9231.765% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -4404.259% |
| BioInvent International AB (publ) | 23.24 Million SEK | -241.249% |
| Alzinova AB (publ) | 800 Thousand SEK | -9815.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 25.512% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -10160.258% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 12.585% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -158.607% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 65.733% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -7375.966% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |